ClinicalTrials.gg
Active, not recruitingNCT06034028JVTF EFSUpdated Jul 11, 2025

J-Valve TF Early Feasibility Study

An interventional study of J-Valve TF System in Aortic Valve Disease, Aortic Valve Insufficiency and Aortic Regurgitation, sponsored by JC Medical, Inc., an affiliate of Edwards Lifesciences LLC. Active, not recruiting at 9 sites in United States. Per ClinicalTrials.gov, last updated 2025-07-11.

Primary conditionAortic Valve InsufficiencyRegistry: Aortic Valve DiseaseReclassifiedWhy we changed it
Registry
Aortic Valve Disease — the first condition term the registry derived for this study.
ClinicalTrials.gg
Aortic Valve Insufficiency
Why
  1. The study's listed conditions name Aortic Valve Insufficiency, a narrower term within Aortic Valve Disease.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by JC Medical, Inc., an affiliate of Edwards Lifesciences LLC (part of Edwards Lifesciences) · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Aortic Valve Insufficiency by Edwards Lifesciences — 1 open to participants now, 4 under way, none of them phase 3. Aortic Valve Insufficiency · Edwards Lifesciences.

Enrollment
10th of 10
25 · median 164
Started
2023
with 1 other
No phase
10 of 11
1 open now
Registered
9th of 11
by date

Among the 11 studies in Aortic Valve Insufficiency by Edwards Lifesciences, this one is the 10th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2023, is one of 10 with no phase, and was the 9th registered.

Aortic Valve Insufficiency

171 studies on the registry are indexed under Aortic Valve Insufficiency; 56 are open to participants now.

Browse Aortic Valve Insufficiency studies →

Open to participants now

1 of the 11 studies in Aortic Valve Insufficiency by Edwards Lifesciences is open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 39 Aortic Valve Insufficiency studies recruiting now, 31 (79%) set no upper age limit and 2 (5%) stop at 75 or younger; 4 take children under 18; 4 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Aortic Valve Insufficiency by Edwards Lifesciences, or all of them as a file.
02

Study summary

The main objective of this study is to assess the preliminary safety and effectiveness of the J-Valve TF System in patients with symptomatic severe native aortic regurgitation who are judged by a multi-disciplinary heart team to be eligible for the device and to be at high risk for open surgical aortic valve replacement.

Read the detailed description

The EFS is a prospective, single arm, multi-center, interventional study that will enroll up to 25 subjects in up to 15 centers in the United States and/or Canada and report the primary endpoint of all-cause death or disabling stroke at 30 days.

03

Conditions studied

  • Aortic Valve Disease
  • Aortic Valve Insufficiency
  • Aortic Regurgitation

Browse trials for

Keywords

  • J-Valve TF System
  • Transcatheter Aortic Valve Replacement
  • Transcatheter Aortic Valve Implantation
  • Transcatheter Heart Valve
  • Transfemoral
  • TAVR
  • TAVI
  • THV
  • VHD
  • Valvular Heart Disease
  • Valve Disease
04

In context

Aortic Valve Insufficiency Reclassified

171 studies on the registry are indexed under Aortic Valve Insufficiency; 56 are open to participants now.

This study's enrollment of 25 is below the median of 123 across 92 interventional studies indexed under Aortic Valve Insufficiency.

Browse Aortic Valve Insufficiency studies →

Lead sponsor

JC Medical, Inc., an affiliate of Edwards Lifesciences LLC is the lead sponsor of 3 studies on the registry; none are open to participants now.

First submitted before JC Medical, Inc. became part of Edwards Lifesciences.

Compared within Aortic Valve Insufficiency, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Aortic Valve Disease. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient has symptomatic ( FC ≥ IIs) severe (≥3+) native AR (per 2020 ACC/AHA Guideline for Management of Patients with Valvular Heart Disease) diagnosed by echocardiography. Patients will be assessed according to the current American Society of Echocardiography Guidelines for Non-invasive Evaluation of Native Valve Regurgitation. Transesophageal echocardiography (TEE) or cardiac MRI (CMR) will be used in case of indeterminant AR;
  • Patient is judged by a multi-disciplinary heart team to be at high risk for surgery, based on the ACC/AHA guidelines for management of patients with valvular heart disease: STS-PROM score ≥8%, or if \<8%, significant co-morbidities that are not captured by the STS-PROM score (e.g., ≥2 frailty indices, 1 to 2 major organ system compromise, the presence of certain procedure-specific factors that affect surgical mortality), based on the consensus of a multi-disciplinary heart team;
  • Patient has suitable anatomy for J-Valve implantation (see anatomic exclusions below);
  • Patient or the patient's legal representative has provided written ;
  • Patient or patient's legal representative agrees to comply with all required post-procedure follow-up visits.

Exclusion criteria

Exclusion Criteria:

  • Patients that are at prohibitive surgical risk (predicted risk for mortality or major morbidity at 30 days >50% with SAVR);
  • Mixed aortic valve disease, defined as coexistence of > moderate aortic valve stenosis with severe AR;
  • Known or to aspirin, heparin, bivalirudin, ticlopidine, clopidogrel, Nitinol (Nickel, Titanium, Aluminum) or sensitivity to contrast media, which cannot be adequately premedicated;
  • Blood dyscrasias as defined: leukopenia (WBC \<1000 mm3), thrombocytopenia ( count \<50,000 cells/mm3), history of bleeding diathesis or coagulopathy;
  • Active infection, including infective endocarditis;
  • Liver failure (Child-C);
  • Reduced left ventricular function with (LVEF) \<25% as measured by resting echocardiogram;
  • Uncontrolled atrial fibrillation (e.g., resting heart rate >120 bpm);
  • Pregnancy or intent to become pregnant prior to completion of all protocol follow-up requirements;
  • Renal insufficiency ( \<25) and/or end stage renal disease requiring chronic dialysis;
  • Pulmonary Hypertension (systolic pressure ≥2/3 of systemic);
  • Severe (COPD) = requiring or requiring continuous home O2
  • Severe mitral or severe tricuspid regurgitation or stenosis;
  • Symptomatic carotid or vertebral artery disease or successful treatment of carotid stenosis within six weeks of treatment;
  • Cardiogenic shock manifested by low cardiac output, vasopressor dependence, or mechanical hemodynamic support;
  • Recent (within 6 months of treatment) cerebrovascular accident (CVA) or (TIA);
  • Active gastrointestinal (GI) bleeding that would preclude anticoagulation;
  • Untreated multivessel coronary artery disease with a Syntax score >22 and/or unprotected left main coronary artery;
  • Evidence of acute myocardial infarction within 1 month of intended procedure;
  • PCI within 30 days of intended procedure;
  • Estimated of less than 24 months due to associated (excluding cardiac) co-morbid conditions;
  • Left Ventricular Assist Device (LVAD) dependent;
  • Participating in another study that may influence the outcome of this study;
  • Need for emergency surgery for any reason;
  • Previous aortic bioprosthesis or mechanical implant.

Anatomic Exclusion Criteria:

  • Ascending Aortic diameter >5 cm;
  • Aortic Annulus Perimeter \<57 mm or >104 mm;
  • Access vessel minimum diameter \<5.5 mm;
  • LVEDD >75 mm;
  • Bicuspid aortic valve disease;
  • Congenital univentricle or other condition that, in the opinion of the investigator and/or consulting physician, may constitute an unwarranted surgical risk.
  • Abdominal aortic aneurysm ≥ 4.0 cm;
  • Aorto-iliac disease requiring intervention to facilitate delivery of access sheath;
  • Excessive tortuosity of delivery system pathway, defined as severe tortuosity of multiple vessels including iliofemoral, descending aorta, ascending aorta, aortic arch, and aortic angle >80⁰. In most cases, this exclusion will be identified and assigned following review by the multi-disciplinary Screening Committee.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    J-Valve TF System

    Device: J-Valve TF System

Interventions

  • DeviceJ-Valve TF System

    The J-Valve TF System is a transcatheter aortic valve replacement system that consists of the J-Valve TF Bioprosthesis, J-Valve TF Delivery Device, and Loading Accessories.

07

What researchers measure

Primary outcomes

  1. Number of patients that do not experience death or disabling stroke

    Freedom from death or disabling stroke Disabling stroke is evaluated using a standardized scale

    Time frame: 30 days after the valve procedure

Secondary outcomes

  1. Number of patients and procedures achieving technical success

    Procedures achieving the following: * Patient is alive; * There was successful access, delivery of the valve, and retrieval of the delivery device; * There was correct positioning of a single prosthetic heart valve into the proper anatomical location; * There was no need for surgery or intervention due to the device, except permanent pacemaker placement, or for a major complication that it vascular, access-related, or cardiac in nature

    Time frame: At point patient exits the procedure room

  2. Number of patients and procedures achieving device success

    * There was successful access, delivery of the valve, and retrieval of the delivery device; * There was correct positioning of a single prosthetic heart valve into the proper anatomical location; * There was no need for surgery or intervention due to the device, except permanent pacemaker placement, or for a major complication that it vascular, access-related, or cardiac in nature; * Patient is alive; * There was not surgery or intervention due to the device, except permanent pacemaker placement, or for a major complication that it vascular, access-related, or cardiac in nature; * The valve was performing as intended, measured by echocardiography

    Time frame: 30 days after the valve procedure

  3. Number of patients with a safety-related event outcome

    Freedom from: * All-cause death; * All stroke; * Valve Academic Research Consortium (VARC)-3 type 2-4 bleeding; * Major vascular, access-related, or cardiac structural complication; * Acute kidney injury stage 3 or 4; * Moderate or severe aortic regurgitation; * New permanent pacemaker due to procedure related conduction abnormalities; * Surgery or intervention related to the device.

    Time frame: 30 days after the valve procedure

  4. Number of patients experiencing success

    No re-hospitalization or re-interventions for the underlying condition and improvement, from baseline, in symptoms, which are measured using the Kansas City Cardiomyopathy Questionnaire (KCCQ) Overall Summary (OS) score. Success in an increase from baseline of 10 or more points on the KCCQ-OS score.

    Time frame: 1 year after the valve procedure

  5. Number of patients meeting clinical efficacy outcome at 2 years

    * Freedom-from all-cause death; * Freedom from all stroke; * Freedom from hospitalization for procedure- or valve-related causes; * Freedom from KCCQ-OS score \< 45 or decline from baseline of \>10 points; * Good Outcome: Alive with change in KCCQ-OS score \>=10 points; * Excellent outcome: Alive with change in KCCQ-OS score \>=20 points.

    Time frame: 2 years after the valve procedure

  6. Number of patients meeting clinical efficacy outcome at 3 years

    * Freedom-from all-cause death; * Freedom from all stroke; * Freedom from hospitalization for procedure- or valve-related causes; * Freedom from KCCQ-OS score \< 45 or decline from baseline of \>10 points; * Good Outcome: Alive with change in KCCQ-OS score \>=10 points; * Excellent outcome: Alive with change in KCCQ-OS score \>=20 points.

    Time frame: 3 years after the valve procedure

  7. Number of patients meeting clinical efficacy outcome at 4 years

    * Freedom-from all-cause death; * Freedom from all stroke; * Freedom from hospitalization for procedure- or valve-related causes; * Freedom from KCCQ-OS score \< 45 or decline from baseline of \>10 points; * Good Outcome: Alive with change in KCCQ-OS score \>=10 points; * Excellent outcome: Alive with change in KCCQ-OS score \>=20 points.

    Time frame: 4 years after the valve procedure

  8. Number of patients meeting clinical efficacy outcome at 5 years

    * Freedom-from all-cause death; * Freedom from all stroke; * Freedom from hospitalization for procedure- or valve-related causes; * Freedom from KCCQ-OS score \< 45 or decline from baseline of \>10 points; * Good Outcome: Alive with change in KCCQ-OS score \>=10 points; * Excellent outcome: Alive with change in KCCQ-OS score \>=20 points.

    Time frame: 5 years after the valve procedure

  9. Number of patients achieving long-term clinical efficacy for valve function

    Freedom from: * Bioprosthetic valve failure (defined as Valve-related mortality or aortic valve re-operation/re-intervention or Stage 3 hemodynamic valve deterioration); * Stroke or peripheral embolism (presumably valve- related, after ruling out other non-valve etiologies); * VARC-3 Type 2-4 bleeding secondary to or exacerbated by antiplatelet * or anticoagulant agents, used specifically for valve- related concerns.

    Time frame: 5 years after the valve procedure

08

Study locations

9 sites
09

References and documents

Publications

  • Writing Committee Members; Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP 3rd, Gentile F, Jneid H, Krieger EV, Mack M, McLeod C, O'Gara PT, Rigolin VH, Sundt TM 3rd, Thompson A, Toly C. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2021 Feb 2;77(4):e25-e197. doi: 10.1016/j.jacc.2020.11.018. Epub 2020 Dec 17. No abstract available. PubMed 33342586 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2023 to primary completion in Jul 2024, 9 months.

Of 44 interventional studies with no phase under Aortic Valve Insufficiency, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 74. This study's 9 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2023
First posted
Sep 13, 2023
StartActual
Oct 16, 2023
Primary completionActual
Jul 17, 2024
CompletionEst.
Aug 25, 2029
Last update
Jul 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06034028
Responsible party
Sponsor
First posted
Sep 13, 2023
Start date
Oct 16, 2023
Primary completion
Jul 17, 2024
Completion
Aug 25, 2029 (estimated)
Last update
Jul 11, 2025

Study contacts

Dean J Kereiakes, MD
principal investigator · The Christ Hospital
Michael J Reardon, MD
principal investigator · The Methodist Hospital Research Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion